What the FDA labels say about taking them together
Cobicistat and lomitapide
Cobicistat's FDA label of February 10, 2026 names lomitapide in its contraindications section; the lomitapide label PlainMeds reads does not name cobicistat. The cobicistat label: “Coadministration with lomitapide is contraindicated due to potential for markedly increased transaminases.”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the lomitapide FDA label on DailyMed (effective March 30, 2026, Chiesi USA, Inc.).
What does the cobicistat label say about lomitapide?
Cobicistat label, contraindicationsSt. John's wort ( Hypericum perforatum ) Hormonal Contraceptives: drospirenone/ ethinyl estradiol Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Non-nucleoside Reverse Transcriptase Inhibitor: nevirapine Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as Revatio ® for the treatment of pulmonary arterial hypertension Protease Inhibitor: indinavir Sedative/hypnotics triazolam, orally administered midazolam Coadministration with certain drugs for which altered plasma concentrations are associated with serious and/or life-threatening events or loss of therapeutic effect.
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: Other lipid-modifying agents: lomitapide; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ lomitapide; Clinical Comment: Coadministration with lomitapide is contraindicated due to potential for markedly increased transaminases.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the lomitapide label say about cobicistat?
Lomitapide's label (effective March 30, 2026) does not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Juxtapid), Chiesi USA, Inc., effective March 30, 2026 (SPL set 61a0be9d-ee58-43e0-b5cb-141011835081), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Lomitapide | |
|---|---|---|
| Labeled for | HIV | High cholesterol |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once